Toronto Stock Exchange Symbol: MS
EDMONTON, Sept. 19 /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX:
MS), a leading developer in the treatment of multiple sclerosis (MS), today
announced that Mr. Kevin Giese, President and CEO, will present at the UBS
Global Life Sciences Conference in New York.
WHEN: Monday September 22nd at 10:00am (Eastern Time)
WHERE: Grand Hyatt New York, New York
About BioMS Medical Corp.
BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, dirucotide (MBP8298), is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. It additionally is being evaluated for relapsing remitting MS patients in a Phase II trial in Europe entitled MINDSET-01. In December 2007, BioMS entered into a licensing and development agreement granting Eli Lilly and Company exclusive worldwide rights to dirucotide (MBP8298), in exchange for an $87 million upfront payment, milestone payments and escalating royalties on sales. For further information please visit our website at http://www.biomsmedical.com.
This press release may contain forward-looking statements, which
reflect the Company's current expectation regarding future events. These
forward-looking statements involve risks and uncertainties that may cause
actual results, events or developments to be materially different from any
future results, events or developments expressed or implied by such
forward-looking statements. Such factors include, but are not limited to,
changing market conditions, the successful and timely completion of
clinical studies, the establishment of corporate alliances, the impact of
|SOURCE BioMS Medical Corp.|
Copyright©2008 PR Newswire.
All rights reserved